Q4 2024 Novo Nordisk A/S Earnings Call Transcript
Key Points
- Novo Nordisk AS (NVO) reported a strong 26% sales growth and 26% operating profit growth for 2024.
- The company expanded its patient reach, now serving over 45 million patients with diabetes and obesity treatments.
- Obesity care sales increased by 57%, driven by significant growth in both North America and international operations.
- Novo Nordisk AS (NVO) maintained its leadership in the GLP-1 market, serving nearly two-thirds of all patients on GLP-1 treatments.
- The company completed the acquisition of Catalent sites, enhancing its global fill and finish footprint, which will support future market supply expansion.
- Total carbon emissions rose by 23% due to increased production volumes and capital expenditure investments.
- Research and development costs increased by 48%, reflecting higher clinical trial activity and impairment losses related to intangible assets.
- The net financial items showed a net loss of DKK1.1 billion, primarily due to losses on non-hedged currencies.
- The effective tax rate increased to 20.6% in 2024, compared to 20.1% in 2023.
- Free cash flow was negative at minus DKK14.7 billion, impacted by significant capital expenditures and the Catalent site acquisition.
Good day and thank you for standing by. Welcome to the full year 2024 Novo Nordisk earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Jacob Martin Rode, Head of Investor Relations.
/-
Thank you. Welcome to this Novo Nordisk Earnings call for the full year of 2024. My name is Jacob Martin, and I'm the Head of Investor Relations at Novo Nordisk.
With me today, I have CEO of Novo Nordisk. Lars Jorgensen, Executive Vice President and Head of Commercial Strategy and Corporate Affairs, Camilla Sylvest, Executive Vice President, US Operations and Head of Global Business Development, Dave Moore, Executive Vice President and Head of Development, Martin Hollinger; and finally, Chief Financial Officer, Karsten Knudsen. All speakers will be available for the Q&A session.
Today's announcement and the slides for this
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
